IP Verse

Oral Formulations Of Deferasirox

Patent No. EP3124018 (titled "Oral Formulations Of Deferasirox") was filed by Novartis on Mar 6, 2014. The application was issued on Apr 24, 2024.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
HGFSep 20, 2018HGF
TEVA PHARMACEUTICALSSep 20, 2018ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3124018

NOVARTIS
Application Number
EP16188627A
Filing Date
Mar 6, 2014
Status
Patent Maintained As Amended
Mar 22, 2024
Publication Date
Apr 24, 2024
External Links
Slate, Register , Google Patents